EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024.08.26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024.08.26

Date

Title

2024-01-03

Change of Address of Head Office and Principal Place of Business in Hong Kong

2023-08-16

Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance

2023-08-16

Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%

2023-07-26

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

2023-06-30

EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”

2023-04-14

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

2023-04-11

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China

2023-03-08

Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT